Evidence map›Paper›PMID 29513197›Full record

ArticleBMC genomics2017

An improved burden-test pipeline for identifying associations from rare germline and somatic variants.

Yu Geng, Zhongmeng Zhao, Xuanping Zhang, Wenke Wang, Xingjian Cui, Kai Ye, Xiao Xiao, Jiayin Wang

Abstract read
In one paragraph

Article in BMC genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. [An improved association analysis pipeline for tumor susceptibility variant in haplotype amplification area].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yu GengSchool of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China.
Zhongmeng ZhaoSchool of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China. zmzhao@mail.xjtu.edu.cn.
Xuanping ZhangSchool of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China.
Wenke WangSchool of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China.
Xingjian CuiSchool of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China.
Kai YeSchool of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China.
Xiao XiaoInstitute of Data Science and Information Quality, Shaanxi Engineering Research Center of Medical and Health Big Data, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China.
Jiayin WangSchool of Management, Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China. wangjiayin@mail.xjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdentifying rare germline and somatic variants associated with cancer progression is an important research topic in cancer genomics. Although many approaches are proposed for rare variant association study, they are not fit for cancer sequencing data due to multiple issues, such as overly relying on pre-selection, losing sight of interacting hotspots, etc.

resultsIn this article, we propose an improved pipeline to identify germline variant and somatic mutation interactions influencing cancer susceptibility from pair-wise cancer sequencing data. The proposed pipeline, RareProb-C performs an algorithmic selection on the given variants by incorporating the variant allelic frequencies. The interactions among the variants are considered within the regions which are limited by a four-gamete test. Then it filters singular cases according to the posterior probability at each site. Finally, it outputs the selected candidates that pass a collapse test.

conclusionsWe apply RareProb-C on a series of carefully constructed simulation cases and it outperforms six existing genetic model-free approaches. We also test RareProb-C on 429 TCGA ovarian cancer cases, and RareProb-C successfully identifies the known highlighted variants which are considered increasing disease susceptibilities.

Indexed as

AlgorithmsDisease ProgressionDNA Mutational AnalysisGenomicsGerm-Line MutationNeoplasms

Identifiers

PMID29513197
PMCPMC5657102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.